The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signaling network: evidence in experimental neuroblastoma

New methods to control neuroblastoma growth

(2014) Paul Dent   CANCER BIOLOGY & THERAPY

A Novel Radiotracer to Image Glycogen Metabolism in Tumors by Positron Emission Tomography

(2014) T. H. Witney et al.   CANCER RESEARCH

Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells

(2014) Aram Ghalali et al.   CARCINOGENESIS

GSK-3 - at the crossroads of cell death and survival

(2014) U. Maurer et al.   JOURNAL OF CELL SCIENCE

PI3K and cancer: lessons, challenges and opportunities

(2014) David A. Fruman et al.   NATURE REVIEWS DRUG DISCOVERY

Sequential Dosing in Chemosensitization: Targeting the PI3K/Akt/mTOR Pathway in Neuroblastoma

(2014) Mike-Andrew Westhoff et al.   PLoS One

Trophic Activity of Human P2X7 Receptor Isoforms A and B in Osteosarcoma

(2014) Anna Lisa Giuliani et al.   PLoS One

ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment

(2014) G Bianchi et al.   Cell Death & Disease

Platelet-Derived Nucleotides Promote Tumor-Cell Transendothelial Migration and Metastasis via P2Y2 Receptor

(2013) Dagmar Schumacher et al.   CANCER CELL

Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model

(2013) E. L. Williams et al.   CLINICAL CANCER RESEARCH

Oxygen-independent Regulation of HIF-1: Novel Involvement of PI3K/ AKT/mTOR Pathway in Cancer

(2013) Faton Agani et al.   CURRENT CANCER DRUG TARGETS

HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations

(2013) Gregg L. Semenza   JOURNAL OF CLINICAL INVESTIGATION

Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

(2013) Alexandre Puissant et al.   Cancer Discovery

Clinical evaluation of the efficacy of the P2X7purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine

(2012) Edward C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

PI3King on MYCN to Improve Neuroblastoma Therapeutics

(2012) Michael D. Hogarty et al.   CANCER CELL

Expression of P2X7 Receptor Increases In Vivo Tumor Growth

(2012) E. Adinolfi et al.   CANCER RESEARCH

Purines, Purinergic Receptors, and Cancer

(2012) F. Di Virgilio   CANCER RESEARCH

Glucose Utilization via Glycogen Phosphorylase Sustains Proliferation and Prevents Premature Senescence in Cancer Cells

(2012) Elena Favaro et al.   Cell Metabolism

Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress

(2012) Kwai Wa Cheng et al.   EMBO Molecular Medicine

Autocrine regulation of TGF- 1-induced cell migration by exocytosis of ATP and activation of P2 receptors in human lung cancer cells

(2012) E. Takai et al.   JOURNAL OF CELL SCIENCE

Efficacy and Safety of CE-224,535, an Antagonist of P2X7 Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate

(2012) T. C. STOCK et al.   JOURNAL OF RHEUMATOLOGY

The P2X7 receptor is a key modulator of aerobic glycolysis

(2012) F Amoroso et al.   Cell Death & Disease

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

P2X7 Receptors Trigger ATP Exocytosis and Modify Secretory Vesicle Dynamics in Neuroblastoma Cells

(2011) Yolanda Gutiérrez-Martín et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

P2X7 receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness

(2011) B Jelassi et al.   ONCOGENE

Dexamethasone Destabilizes Nmyc to Inhibit the Growth of Hedgehog-Associated Medulloblastoma

(2010) V. M. Heine et al.   CANCER RESEARCH

Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer Immunity

(2010) L. Aymeric et al.   CANCER RESEARCH

Chemotherapy induces ATP release from tumor cells

(2010) Isabelle Martins et al.   CELL CYCLE

Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor

(2010) Elena Adinolfi et al.   FASEB JOURNAL

A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients

(2010) Paolo Fardin et al.   Molecular Cancer

Roles of P2X7 Receptor in Glial and Neuroblastoma Cells: The Therapeutic Potential of P2X7 Receptor Antagonists

(2010) Synthia H. Sun   MOLECULAR NEUROBIOLOGY

Abnormal expression of P2X family receptors in Chinese pediatric acute leukemias

(2009) Jing-Hui Chong et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

ZNF423 Is Critically Required for Retinoic Acid-Induced Differentiation and Is a Marker of Neuroblastoma Outcome

(2009) Sidong Huang et al.   CANCER CELL

Functional decreases in P2X7 receptors are associated with retinoic acid-induced neuronal differentiation of Neuro-2a neuroblastoma cells

(2009) Pei-Yu Wu et al.   CELLULAR SIGNALLING

Ca2+/calmodulin-dependent kinase II signalling cascade mediates P2X7 receptor-dependent inhibition of neuritogenesis in neuroblastoma cells

(2009) Rosa Gómez-Villafuertes et al.   FEBS Journal

Expression of the P2X7Receptor Increases the Ca2+Content of the Endoplasmic Reticulum, Activates NFATc1, and Protects from Apoptosis

(2009) Elena Adinolfi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

P2X7: a growth-promoting receptor—implications for cancer

(2009) Francesco Di Virgilio et al.   Purinergic Signalling

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

(2008) Susan L. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY

N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma

(2008) J Kang et al.   ONCOGENE